# Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI).

> **NCT05957042** · EARLY_PHASE1 · WITHDRAWN · sponsor: **Milton S. Hershey Medical Center**

## Conditions studied

- Breast Cancer
- Contrast Enhanced Ultrasound

## Interventions

- **DRUG:** Lumason

## Key facts

- **NCT ID:** NCT05957042
- **Lead sponsor:** Milton S. Hershey Medical Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-09-01
- **Primary completion:** 2026-09-01
- **Final completion:** 2031-09-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Responsible Party left the institution and the study will not be started by other investigator
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05957042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05957042, "Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI).". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05957042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*